Agilent Technologies Inc (A – Q4FY20 & FY20) – Performance was positively affected due to recovery of core businesses.

Agilent’s Life Sciences and Applied Markets Group (LSAG) grew a reported 8% year over year to $671mn. The revenue performance reflected generally improving conditions across geographies led by growth in the Food, Pharma, and C&E markets, and highlighted by strength in Cell Analysis and Mass Spectrometry.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q4FY20 & FY20 Results – Overview
– Q4FY20 & FY20 Revenue by Region
– Q4FY20 & FY20 Revenue by Type
– Q4FY20 & FY0 Revenue by End-Markets
– Q4FY20 & FY20 – Segment Performance
– Key Developments
– Guidance
– Conclusion
– GAAP to Non-GAAP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– DuPont Analysis
– ROIC
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competitors
– Key Developments

Valuation and Consensus Performance

– Analyst Recommendations

Market Price Performance

Crispidea Coverage

No of Pages : 60